GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Open to people ages 50 years and up

• Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal.
• Vaccination against Neisseria meningitidis and Streptococcus pneumoniae received at least 2 weeks prior to first dose of investigational product
• Well-demarcated geographic atrophy (GA) due to AMD
• Best-corrected visual acuity (BCVA) letter score of 35 letters (approx. 20/200 Snellen equivalent) or better on the ETDRS chart
• Must have clear ocular media and adequate pupillary dilation in the study eye to permit high-quality fundus imaging

• Clinically-significant abnormalities in medical history
• A lack of full recovery from any infection for at least 14 days prior to the Study Drug administration
• Chronic treatment with steroids, including topically or intravitreally administered
• History or presence of diabetic retinopathy or diabetic macular edema (DME)
• History or presence of a disease other than AMD that could affect vision or safety assessments
• Prior treatment with another investigational drug, biological agent, or device
• Other protocol-specified inclusion/exclusion criteria may apply